Free Trial
NASDAQ:QTEX

QTREX Quantum Q2 2026 Earnings Results & Report

QTREX Quantum logo
$1.14 -0.11 (-8.40%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

QTREX Quantum reported Q2 2026 earnings on September 24, 2026. The company reported EPS of -$0.07, while revenue was $777 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Time
After Market Closes

QTREX Quantum EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

QTREX Quantum Revenue Results

Actual Revenue
$777 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

QTREX Quantum Q2 2026 Earnings FAQ

QTREX Quantum (NASDAQ:QTEX) reported earnings of -$0.07 per share for Q2 2026. The report was announced on Thursday, September 24, 2026.

QTREX Quantum reported revenue of $777 thousand for Q2 2026.

QTREX Quantum Earnings Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
QTREX Quantum Ltd. (QTEX)
See More QTREX Quantum Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like QTREX Quantum? Sign up for Earnings360's daily newsletter to receive timely earnings updates on QTREX Quantum and other key companies, straight to your email.

About QTREX Quantum

Inspira Technologies OXY B.H.N. Ltd. is a medical technology company focused on developing advanced respiratory-support and blood-monitoring solutions for critical-care settings. The company’s technologies are intended to help address complications associated with respiratory failure and improve the management of patients requiring oxygenation support.

Its product portfolio includes the INSPIRA ART system, an extracorporeal respiratory-support platform designed to provide oxygenation while potentially reducing the need for conventional mechanical ventilation or more complex extracorporeal membrane oxygenation procedures. The company is also developing the HYLA blood-sensor technology, which is intended to provide continuous monitoring of blood parameters during treatment.

Inspira Technologies is based in Israel and serves the global medical-device market through the development of products for hospitals and intensive-care environments. The company was founded by Dagi Ben-Noon, who serves as its chief executive officer. Its technologies remain subject to applicable regulatory and clinical-development requirements in the markets where the company seeks commercialization.

View QTREX Quantum Profile